363 related articles for article (PubMed ID: 1388181)
1. Therapeutic dissection after successful coronary balloon angioplasty: no influence on restenosis or on clinical outcome in 693 patients. The MERCATOR Study Group (Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
Hermans WR; Rensing BJ; Foley DP; Deckers JW; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
J Am Coll Cardiol; 1992 Oct; 20(4):767-80. PubMed ID: 1388181
[TBL] [Abstract][Full Text] [Related]
2. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
Circulation; 1992 Jul; 86(1):100-10. PubMed ID: 1535568
[TBL] [Abstract][Full Text] [Related]
3. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group.
Faxon DP
J Am Coll Cardiol; 1995 Feb; 25(2):362-9. PubMed ID: 7829789
[TBL] [Abstract][Full Text] [Related]
4. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
Hermans WR; Foley DP; Rensing BJ; Serruys PW
Am Heart J; 1994 Mar; 127(3):483-94. PubMed ID: 8122593
[TBL] [Abstract][Full Text] [Related]
5. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
Hermans WR; Rensing BJ; Foley DP; Tijssen JG; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
J Cardiovasc Pharmacol; 1993; 22 Suppl 4():S45-57. PubMed ID: 7523772
[TBL] [Abstract][Full Text] [Related]
6. Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR).
Berger PB; Holmes DR; Ohman EM; O'Hanesian MA; Murphy JG; Schwartz RS; Serruys PW; Faxon DP
J Am Coll Cardiol; 1996 Jan; 27(1):1-7. PubMed ID: 8522681
[TBL] [Abstract][Full Text] [Related]
7. Long-term luminal renarrowing after successful elective coronary angioplasty of total occlusions. A quantitative angiographic analysis.
Violaris AG; Melkert R; Serruys PW
Circulation; 1995 Apr; 91(8):2140-50. PubMed ID: 7697842
[TBL] [Abstract][Full Text] [Related]
8. Differences in restenosis propensity of devices for transluminal coronary intervention. A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implantation and excimer laser angioplasty. CARPORT, MERCATOR, MARCATOR, PARK, and BENESTENT Trial Groups.
Foley DP; Melkert R; Umans VA; de Jaegere PP; Strikwerda S; de Feyter PJ; Serruys PW
Eur Heart J; 1995 Oct; 16(10):1331-46. PubMed ID: 8746901
[TBL] [Abstract][Full Text] [Related]
9. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
Bertrand ME; McFadden EP; Fruchart JC; Van Belle E; Commeau P; Grollier G; Bassand JP; Machecourt J; Cassagnes J; Mossard JM; Vacheron A; Castaigne A; Danchin N; Lablanche JM
J Am Coll Cardiol; 1997 Oct; 30(4):863-9. PubMed ID: 9316510
[TBL] [Abstract][Full Text] [Related]
10. Effect of cilazapril on vascular restenosis after percutaneous transluminal coronary angioplasty.
Yamabe T; Imazu M; Yamamoto H; Ueda H; Hattori Y; Hayashi Y; Sekiguchi Y; Ito M; Yamakido M
Coron Artery Dis; 1995 Jul; 6(7):573-9. PubMed ID: 7582196
[TBL] [Abstract][Full Text] [Related]
11. Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty. A quantitative angiographic analysis of 3336 lesions.
Violaris AG; Melkert R; Serruys PW
Circulation; 1994 Nov; 90(5):2267-79. PubMed ID: 7955183
[TBL] [Abstract][Full Text] [Related]
12. Restenosis after delayed coronary angioplasty of the culprit vessel in patients with a recent myocardial infarction treated by thrombolysis.
Bauters C; Khanoyan P; McFadden EP; Quandalle P; Lablanche JM; Bertrand ME
Circulation; 1995 Mar; 91(5):1410-8. PubMed ID: 7867181
[TBL] [Abstract][Full Text] [Related]
13. Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty.
Foley DP; Melkert R; Serruys PW
Circulation; 1994 Sep; 90(3):1239-51. PubMed ID: 8087933
[TBL] [Abstract][Full Text] [Related]
14. Emergency coronary stenting for dissection during percutaneous transluminal coronary angioplasty: angiographic follow-up after stenting and after repeat angioplasty of the stented segment.
Schömig A; Kastrati A; Dietz R; Rauch B; Neumann FJ; Katus HH; Busch U
J Am Coll Cardiol; 1994 Apr; 23(5):1053-60. PubMed ID: 8144767
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty.
Desmet W; Vrolix M; De Scheerder I; Van Lierde J; Willems JL; Piessens J
Circulation; 1994 Jan; 89(1):385-92. PubMed ID: 8281674
[TBL] [Abstract][Full Text] [Related]
16. Restenosis after directional coronary atherectomy and balloon angioplasty: comparative analysis based on matched lesions.
Umans VA; Hermans W; Foley DP; Strikwerda S; van den Brand M; de Jaegere P; de Feyter PJ; Serruys PW
J Am Coll Cardiol; 1993 May; 21(6):1382-90. PubMed ID: 8473645
[TBL] [Abstract][Full Text] [Related]
17. The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome.
Brack MJ; Ray S; Chauhan A; Fox J; Hubner PJ; Schofield P; Harley A; Gershlick AH
J Am Coll Cardiol; 1995 Oct; 26(4):947-54. PubMed ID: 7560622
[TBL] [Abstract][Full Text] [Related]
18. Restenosis after coronary angioplasty for rapidly progressive coronary stenosis.
Bauters C; Passart F; Lablanche JM; McFadden EP; Hamon M; Bertrand ME
Eur Heart J; 1996 Nov; 17(11):1671-7. PubMed ID: 8922915
[TBL] [Abstract][Full Text] [Related]
19. Clinical and angiographic results of transluminal extraction coronary atherectomy in saphenous vein bypass grafts.
Safian RD; Grines CL; May MA; Lichtenberg A; Juran N; Schreiber TL; Pavlides G; Meany TB; Savas V; O'Neill WW
Circulation; 1994 Jan; 89(1):302-12. PubMed ID: 8281662
[TBL] [Abstract][Full Text] [Related]
20. Long-term angiographic and clinical outcome after implantation of a balloon-expandable stent in the native coronary circulation. Palmaz-Schatz Stent Study Group.
Savage MP; Fischman DL; Schatz RA; Teirstein PS; Leon MB; Baim D; Ellis SG; Topol EJ; Hirshfeld JW; Cleman MW
J Am Coll Cardiol; 1994 Nov; 24(5):1207-12. PubMed ID: 7930240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
